15-Deoxy-Δ 12,14-prostaglandin-J 2 inhibits expression of eNOS in human endothelial cells

Prostaglandins and Other Lipid Mediators

Volumn 74, Issue 1-4, 2004, Pages 11-28

  Józkowicz, Alicja ^a,b   Nigisch, Anneliese ^b   Winter, Birgitta ^b   Weigel, Guenter ^b   Huk, Ihor ^b   Dulak, Józef ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

15 Deoxy 12,14 Prostaglandin J 2; eNOS; HUVEC; PPAR

Indexed keywords

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; ACTIVATED PROTEIN 1; DELTA12 PROSTAGLANDIN J2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; DRUG DERIVATIVE; NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRIMER DNA; PROSTAGLANDIN D2; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; EXPOSURE; GENETIC STABILITY; HUMAN; HUMAN CELL; INCUBATION TIME; NEWBORN; OBSERVATION; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UMBILICAL VEIN; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM;

BASE SEQUENCE; CELL LINE; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; POLYMERASE CHAIN REACTION; PPAR GAMMA; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN D2; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1;

EID: 5444219932     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2004.05.001     Document Type: Article

References (48)

1. D.J. Mangelsdorf, and R.M. Evans The RXR heterodimers and orphan receptors Cell 83 1995 841
2. N. Marx, U. Schonbeck, M.A. Lazar, P. Libby, and J. Plutzky Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circ Res 83 1998 1097
3. X. Xin, S. Yang, J. Kowalski, and M.E. Gerritsen Peroxisome proliferator-activated receptor-γ ligands are potent inhibitors of angiogenesis in vitro and in vivo J Biol Chem 274 1999 9116
4. 2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-γ-independent manner Prostaglandins Other Lipid Mediat 66 2001 165
5. J.M. Lehmann, L.B. Moore, T.A. Smith-Olivier, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPARγ) J Biol Chem 270 1995 12953
6. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation Nature 391 1998 79
7. 2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation Cell 83 1995 813
8. 2: a biochemical perspective Prostaglandins Leukot Essent Fatty Acids 37 1989 219
9. 2 synthase expression in vascular endothelial cells Circ Res 86 2000 967
10. 2, the peroxisome proliferator-activated receptor-γ ligand, in urine Clin Chem 47 2001 768
11. 2 metabolite generated during inflammatory processes J Biol Chem 277 2002 10459
12. 2 on VEGF synthesis depends on the induction of heme oxygenase-1 Antioxidant Redox Signal 4 2002 577
13. 2 inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPARγ Biochem Biophys Res Commun 298 2002 128
14. 2 upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor-γ ActaBiochim Pol 50 2003 677
15. 2 inhibits the expression of granulocyte-macrophage colony-stimulating factor in endothelial cells stimulated with lipopolysaccharide Prostaglandins Other Lipid Mediat 71 2003 293
16. 2 inhibits CX3CL1/fractalkine expression in human endothelial cells Immunol Cell Biol 80 2002 531
17. 2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade Thromb Haemost 88 2002 524
18. 2 J Biol Chem 274 1999 17042
19. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor-γ ligands increase release of nitric oxide from endothelial cells Arterioscler Thromb Vasc Biol 23 2003 52
20. J.P. Cooke, and V.J. Dzau Nitric oxide synthase: role in the genesis of vascular disease Annu Rev Med 48 1997 489
21. F. Karantzoulis-Fegaras, H. Antoniou, and S.L. Lai Characterization of the human endothelial nitric-oxide synthase promoter J Biol Chem 274 1999 3076
22. K. Yu, W. Bayona, and C.B. Kallens Differential activation of peroxisome proliferator-activated receptors by eicosanoids J Biol Chem 270 1995 23975
23. D.H. Wright, K.M. Metters, M. Abramowitz, and A.W. Ford-Hutchinson Characterization of the recombinant human prostanoid DP receptor and identification of L-644698, a novel selective DP agonists Br J Pharmacol 123 1998 1317
24. M. Kondo, T. Oya-Ito, T. Kumagai, T. Osawa, and K. Uchida Cyclopentanone prostaglandins as potential inducers of intracellular oxidative stress J Biol Chem 276 2001 12076
25. R. Zhang, W. Min, and W.C. Sessa Functional analysis of the human endothelial nitric oxide synthase promoter. SP1 and GATA factors are necessary for basal transcription in endothelial cells J Biol Chem 270 1995 15320
26. 2 in the developing choroids Am J Physiol Heart Circ Physiol 278 2000 60
27. U. Laufs, and J.K. Liao Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase J Biol Chem 273 1998 24266
28. M. Yoshizumi, M.A. Perrella, J.C. Burnett Jr., and M.E. Lee Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life Circ Res 1993 73
29. S. Goetze, X.P. Xi, and H. Kawano PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells J Cardiovasc Pharmacol 33 1999 798
30. 2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis J Invest Dermatol 119 2002 609
31. R.M. Breyer, C.K. Bagdassarian, S.A. Myers, and M.D. Breyer Prostanoid receptors: subtypes and signaling Annu Rev Pharmacol Toxicol 41 2001 661
32. 2 inhibition of NFκB-DNA binding through covalent modification of the p50 subunit J Biol Chem 276 2001 35530
33. T. Shibata, T. Yamada, and T. Ishii Thioredoxin as a molecular target of cyclopentenone prostaglandins J Biol Chem 278 2003 26046
34. B. Halliwell, and J.M.C. Gutterige Free radicals in biology and medicine 3rd ed 2001 Oxford Science Publications
35. J. Navarro-Antolin, J. Rey-Campos, and S. Lamas Transcriptional induction of endothelial nitric oxide gene by cyclosporine A. A role for activator protein-1 J Biol Chem 275 2000 3075
36. K. Cieslik, A. Zembowicz, J.L. Tang, and K.K. Wu Transcriptional regulation of endothelial nitric-oxide synthase by lysophosphatidylcholine J Biol Chem 273 1998 4885
37. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129
38. A. Sugawara, A. Uruno, and M. Kudo Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-γ via an interaction with Sp1 in vascular smooth muscle cells J Biol Chem 277 2002 9676
39. R.E. Law, W.P. Meehan, and X.P. Xi Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia J Clin Invest 98 1996 897
40. 2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells Kidney Int 61 2002 1957
41. H. Fahmi, J.P. Pelletier, J.A. Di Battista, H.S. Cheung, J.C. Fernandes, and J. Martel- Pelletier Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1 Osteoarthritis Cartilage 10 2002 100
42. 2 inhibits multiple steps in the NFκB signaling pathway Proc Natl Acad Sci USA 97 2000 4844
43. 2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways FEBS Lett 501 2001 24
44. 2 formation and characterization of its synthetases in various tissues of adult rats Arch Biochem Biophys 260 1988 521
45. Y. Eguchi, N. Eguchi, and H. Oda Expression of lipocalin-like prostaglandin D synthase (β-trace) in human heart and its accumulation in the coronary circulation of angina patients Proc Natl Acad Sci USA 94 1997 14689
46. T. Inoue, K. Takayanagi, and S. Morooka Serum prostaglandin D synthase level after coronary angioplasty may predict occurence of restenosis Thromb Haemost 85 2001 165
47. N. Hirawa, Y. Uehara, and Y. Minoru Lipocalin-type prostaglandin D synthase in essential hypertension Hypertension 39 2002 449
48. P. Tontonoz, L. Nagy, J.G.A. Alvarez, V.A. Thomazy, and R.M. Evans PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 1998 241